Claims for Patent: 8,486,975

Summary for Patent: 8,486,975

Title:	Non-nucleoside reverse transcriptase inhibitors
Abstract:	Heteroaromatic compounds of Formula I: ##STR00001## are HIV reverse transcriptase inhibitors, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Inventor(s):	Burch; Jason (Redwood City, CA), Cote; Bernard (Notre-Dame-de-I'lle-Perrot, CA)
Assignee:	Merck Canada Inc. (Kirkland, Quebec, CA)
Application Number:	13/073,631
Patent Claims:	1. The compound ##STR00056## 2. A pharmaceutical composition comprising an effective amount of the compound according to claim 1 and a pharmaceutically acceptable carrier. 3. A method for the treatment of infection by HIV or for the treatment of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1. 4. The compound ##STR00057## or a pharmaceutically acceptable salt thereof. 5. A pharmaceutical composition comprising an effective amount of the compound according to claim 4 and a pharmaceutically acceptable carrier. 6. A method for the treatment of infection by HIV or for the treatment of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 4.